Skip to main content
Industry News
Rolling submission starts for CTI BioPharma's pacritinib

CTI BioPharma has initiated the rolling market application submission with the FDA to seek its approval for pacritinib as a treatment for patients with myelofibrosis who have severe thrombocytopenia. Pre-commercial activities have begun and planning is underway for a 2021 commercial launch, according to the company.

Full Story: